In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Zai Lab Ltd.

Mixed Q3 For China's Innovative Firms Amid Anti-Graft Campaign

China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.

China Sales & Earnings

LianBio Eyes ‘Strategic Review’ As It Hands Camzyos Asia Rights Back To MyoKardia Parent BMS

BMS, which acquired MyoKardia in 2020 months after LianBio acquired rights in certain Asia-Pacific territories, said the deal would help expand its footprint in China.

Deals Asia Pacific

ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow

Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.

Asia Pacific China

BioNTech In Another China ADC Deal, This Time With Medilink

Medilink’s ADC platform, which addresses the antibody endocytosis process, has received its first endorsement from a major international partner in the form of BioNTech.

China Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Zai Lab Limited
    • Zai Lab (Shanghai) Co., Ltd.
UsernamePublicRestriction

Register